Strategic Acquisition LIDDS has expanded its oncology focus through the acquisition of Noviga Research AB, signaling a potential opportunity to cross-sell NanoZolid delivery capabilities to Noviga's cancer drug programs and leverage combined R&D efforts for joint partnerships or licensing discussions.

Clinical Development Talent With leadership and clinical development teams evolving (CEO changes and Head of Clinical Development appointments), there is a window to engage for collaboration on translational studies, regulatory strategy support, and clinical trial design leveraging NanoZolid’s local, sustained release platform.

NanoZolid Advantage The proprietary NanoZolid platform enabling up to six months of local drug release presents a compelling value proposition for partnerships in oncology and other indications requiring targeted, sustained local delivery, inviting conversations with biotech companies seeking improved pharmacokinetics and reduced systemic exposure.

Early-Stage Bio Partners As a small biotechnology player with revenue below $1M and recent funding, LIDDS could be an attractive partner for co-development agreements, licensing deals, or contract research and manufacturing services to accelerate their pipeline using NanoZolid technology.

Global Collaboration Past collaboration with Johnson & Johnson Enterprise Innovation indicates openness to big-corporate partnerships; engaging large pharma with a focus on oncology and localized delivery could yield licensing, equity, or milestone-driven deals that leverage LIDDS’ innovative platform.